Lotemax® Ointment
Loteprednol 0.5% · ophthalmic ointment
Steroid
Approved uses
Post-operative inflammation and pain following ocular surgery
Approximately a 1/2 inch ribbon into the conjunctival sac(s) QID beginning 24 hours after surgery, continuing through the first 2 post-operative weeks
By day 8, 76% are pain free and 28% have complete resolution of anterior chamber inflammation.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
0.5% ointment (loteprednol etabonate 5 mg/g), 3.5 g tube
Corticosteroid: binds and activates the glucocorticoid receptor and is thought to inhibit prostaglandin production through several independent mechanisms, inhibiting the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation, while probably delaying healing. Systemic exposure from this ointment has not been studied in humans; the label states that QID dosing is not expected to exceed exposures attained with the 0.5% suspension dosed up to 2 drops QID, and in the suspension bioavailability study (1 drop OU 8 times daily for 2 days, or QID for 42 days) plasma drug and primary metabolite stayed below the 1 ng/mL limit of quantitation.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may result in glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma, and monitor IOP if this product is used 10 days or longer, even though it may be difficult in children and uncooperative patients.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing after cataract surgery: Steroids used after cataract surgery may delay healing and increase the incidence of bleb formation.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforations have occurred with topical steroids.
- Renewal beyond 14 days: Initial prescription and renewal past 14 days only after examination with magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Secondary ocular infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions steroids may mask infection or enhance existing infection, and the patient should be re-evaluated if signs and symptoms fail to improve after 2 days.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal keratitis: Fungal corneal infection is particularly prone to develop coincidentally with long-term local steroid use; consider fungal invasion in any persistent corneal ulceration where a steroid has been used or is in use, and culture when appropriate.
- Risk of contamination: Do not touch the eyelid or surrounding areas with the tip of the tube, and keep the cap on the tube when not in use.
- Contact lens wear: Lenses should not be worn during the course of therapy.
- Topical ophthalmic use: This ointment is not indicated for intraocular administration.
Common Side Effects
The most common ocular adverse event in clinical studies was anterior chamber inflammation, at approximately 25%. Other common adverse events, with an incidence of 4% to 5%, were conjunctival hyperemia, corneal edema, and eye pain; many of these events may have been the consequence of the surgical procedure. The only non-ocular adverse event occurring at 1% or more was headache (1.5%). Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Pregnancy: No adequate and well controlled studies in pregnant women. Oral dosing produced teratogenicity at clinically relevant doses, with malformations in rabbits from 1.6 times the recommended human ophthalmic dose (spina bifida including meningocele from 0.1 mg/kg, exencephaly and craniofacial malformations from 6.5 times) and in rats from 41 times. Abortion and embryofetal lethality (resorption) occurred in rabbits from 97 times, and offspring survival was reduced in rats from 4 times. Background risk in the U.S. general population is 2% to 4% for major birth defects and 15% to 20% for miscarriage.
Lactation: No data on the presence of drug in human milk, on effects in the breastfed infant, or on milk production; weigh the developmental and health benefits of breastfeeding against the clinical need and potential adverse effects.
Safety and effectiveness in pediatric patients have not been established.